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Polycyclic aromatic hydrocarbons (PAHs) 
are a large group of organic contaminants, 
characterized by the presence of at least two 
fused aromatic rings. These compounds result 
from pyrolytic processes and the incomplete 
combustion of organic matter at high tem-
peratures, and anthropogenic activities are 
the main source of PAHs in the environment. 
Because of their adverse effects on human 
health, their persistence in environmental 
matrices, and their reactivity and ability to 
transform into more active species, PAHs have 
been classified as priority pollutants by both 
the U.S. Environmental Protection Agency 
(EPA 1994) and the European Environment 
Agency (1999).
PAH health effects have been widely 
studied, primarily because of their poten-
tial carcinogenic and mutagenic proper-
ties. Several toxicological studies in animals 
[World Health Organization–International 
Programme on Chemical Safety (WHO–
IPCS) 1998] and occupational studies in 
humans (Armstrong et al. 2004) demonstrate 
an excess risk of lung cancer associated with 
PAH inhalation. The potential influence of 
PAH exposure on the development of blad-
der and urinary system cancer also has been 
studied (Bosetti et al. 2007). In general, the 
carcinogenic properties of PAHs increase 
with the number of aromatic rings. Benzo[a]
pyrene (BaP) has been the most extensively 
studied PAH and is the usual marker for 
carcinogenic levels of PAHs in environmen-
tal studies. However, uncertainties about 
the suitability of BaP as a cancer risk indica-
tor have also been discussed (Boström et al. 
2002). The International Agency for Research 
on Cancer (IARC) classified BaP as carci-
nogenic to humans (group 1); other PAHs, 
such as dibenzo[a,h]anthracene (DahA), as 
probably carcinogenic to humans (group 2A); 
and other PAHs, such as naphthalene (Nap), 
benzo[a]anthracene (BaA), chrysene (Chr), 
benzo[b]fluoranthene (BbF), benzo[j]fluoran-
thene (BjF), and indeno[1,2,3-cd]pyrene (Ind) 
as possibly carcinogenic to humans (group 
2B). PAHs can also metabolize and become 
reactive electrophilic intermediates that can 
form DNA adducts, which may induce muta-
tions and ultimately tumors (IARC 2010). 
Some PAHs, such as fluoranthene (FluT), 
which IARC classified as weak carcinogens 
(group 3), have mutagenic characteristics and 
may therefore play an important role in car-
cinogenesis (Boström et al. 2002).
Studies of other outcomes have sug-
gested effects of PAHs on the development 
of arterio  sclerosis (WHO 2000), reproduc-
tive outcomes such as intrauterine growth 
retardation (Dejmek et al. 2000; Šrám et al. 
2005), and children’s neurological devel-
opment (Perera et al. 2009). Furthermore, 
because PAHs are highly hydrophobic, they 
have an affinity for environmental matrices 
such as sediments, soils, and biota and can 
bioaccumulate in adipose tissues and become 
magnified through the food chain (WHO–
IPCS 1998). Because of their lipophilic char-
acteristics and limited biodegradation, PAHs 
are classified as persistent organic pollutants.
Ingestion is quantitatively the main route 
for PAH human exposure. However, inhala-
tion is also a significant route because of the 
ubiquitous presence of these compounds in 
the atmosphere [Agency for Toxic Substances 
and Disease Registry (ATSDR) 1995; Li 
et al. 2010]. PAHs can be associated with 
the atmospheric gas phase and particulate 
phase (Ravindra et al. 2008; WHO–IPCS 
1998). The most lipophilic compounds are 
mainly associated with the particle fraction, 
which can accumulate in the tracheobronchial 
  epithelium, where they increase PAH con-
centrations even at low environmental PAH 
exposures (Boström et al. 2002; Gerde et al. 
1993). In contrast, PAHs present in the gas 
phase or those that rapidly elute from particles 
upon inhalation can reach the alveolar epithe-
lium and rapidly enter the circulatory system 
(Boström et al. 2002; Gerde et al. 1993).
Risk estimation for PAH exposures is com-
plex for several reasons. There are few reported 
human epidemiological studies of individ-
ual PAHs, and individual PAHs are likely to 
induce cancer through different mechanisms. 
As mentioned above, BaP is the most stud-
ied PAH, and other PAHs have been ranked 
according to cancer potency relative to BaP 
using toxic equivalence factors (TEFs). The 
application of TEFs combined with the WHO 
quantitative risk assessment (QRA) methodol-
ogy (WHO 2000) can be used to estimate the 
excess lifetime risk of lung cancer due to PAH 
exposures. This methodology has been used to 
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Ba c k g r o u n d: Inhalation is one of the main means of human exposure to polycyclic aromatic 
hydrocarbons (PAHs) because of their ubiquitous presence in the atmosphere. However, most stud-
ies have considered only PAHs found in the particle phase and have omitted the contribution of the 
gas-phase PAHs to the risk.
oB j e c t i v e: We estimated the lifetime lung cancer risk from PAH exposure by inhalation in people 
living next to the largest chemical site in Southern Europe and the Mediterranean area.
Me t h o d s : We determined 18 PAHs in the atmospheric gas and particle phase. We monitored 
the PAHs for 1 year in three locations near the chemical site in different seasons. We used toxic 
equivalence factors to calculate benzo[a]pyrene (BaP) equivalents (BaP-eq) for individual PAHs and 
applied the World Health Organization unit risk (UR) for BaP (UR = 8.7 × 10–5) to estimate life-
time cancer risks due to PAH exposures.
re s u l t s: We observed some spatial and seasonal variability in PAH concentrations. The contribu-
tion of gas-phase PAHs to the total BaP-eq value was between 34% and 86%. The total estimated 
average lifetime lung cancer risk due to PAH exposure in the study area was 1.2 × 10–4.
co n c l u s i o n s: The estimated risk was higher than values recommended by the World Health 
Organization and U.S. Environmental Protection Agency but lower than the threshold value of 10–3 
that is considered an indication of definite risk according to similar risk studies. The results also 
showed that risk may be underestimated if the contributions of gas-phase PAHs are not considered.
key w o r d s : air quality, gas phase, particulate phase, polycyclic aromatic hydrocarbons, risk assess-
ment. Environ Health Perspect 119:1110–1116 (2011).  doi:10.1289/ehp.1002855 [Online 8 April 
2011]Risk assessment of PAHs near industrial sites
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establish guideline values for PAH exposures 
and inform environmental policies (Morello-
Frosch et al. 2000).
The aim of the present study is to estimate 
the lifetime lung cancer risk of PAH exposure 
by inhalation in people living in urban and 
suburban areas near an important industrial 
chemical site in the Tarragona region (north-
eastern Spain). To that end, we selected 18 
PAH compounds [most of them included in 
the U.S. EPA Priority List (ATSDR 2007)], 
in both the gas and particle phases. We moni-
tored three locations near the two industrial 
complexes in the region from June 2008 to 
June 2009. We evaluated the distribution of 
PAHs in the gas and particle phase, their sea-
sonal and spatial distributions, and the contri-
bution of individual PAHs to estimated risks.
Few studies related to industrial atmo-
spheres consider the contribution of both the 
atmospheric gas phase and the particle phase 
to risk (Liu et al. 2010). To our knowledge, 
this is the first study to estimate lifetime lung 
cancer risk due to inhalation of PAHs in both 
the gas and particle phases among people liv-
ing near a petrochemical and chemical indus-
trial site with these characteristics.
Materials and Methods
Study area. The largest chemical site in 
Southern Europe and the Mediterranean area 
is located in the Tarragona region (European 
Chemical Regions Network 2010). Most of 
the chemical industries are located in two 
areas known as the North and the South 
Industrial Complexes. The North Industrial 
Complex has an area of 470 ha and includes 
an oil refinery and other chemical industries. 
Among the products manufactured in the 
North Complex are benzene, ethylene, fuel 
oil, gasoline, kerosene, propylene, propyl-
ene oxide, polypropylene, and styrene. The 
South Industrial Complex occupies an area of 
717 ha and includes several chemical and pet-
rochemical plants. Among the products man-
ufactured in the South Industrial Complex are 
acrylonitrile-butadiene-styrene (ABS), butane, 
chlorine, ethylene oxide, polyethylene, kero-
sene, halogenated organic compounds, poly-
ols, polypropylene, polystyrene, polyethylene, 
polyvinyl chloride, propane, and vinyl acetate. 
The total production of the two complexes is 
about 21 million tons per year (refining, 8.3 
million tons; chemical products, 12.7 mil-
lion tons [Associació Empresarial Química de 
Tarragona (AEQT) 2009]).
Figure 1 shows the map of the study area. 
We selected three sampling sites on the basis 
of their proximity to the industrial complexes 
and the prevailing wind. Site 1 is located in 
Perafort-Puigdelfí, a semirural area < 0.5 km 
east of the North Industrial Complex. Site 2, 
Tarragona-Bonavista, is in a suburban area of 
the main city of Tarragona < 1 km north of 
the South Industrial Complex and < 0.5 km 
from a road with a moderate traffic density 
[14,041 vehicles per day (Spanish Ministry 
of Public Works, personal communication)]. 
Finally, site 3 is also located in Vila-seca, a 
suburban area < 1 km from the west end of 
the South Industrial Complex and < 1 km 
from a road with a moderate traffic density 
(20,049 vehicles per day (Spanish Ministry 
of Public Works, personal communica-
tion). Wind speeds are light (annual average 
< 3 m/sec), and the prevailing wind directions 
are north-northwesterly in cold seasons and 
south-southeasterly in warm seasons.
Sample collection. We collected sam-
ples using a TE-1000 polyurethane foam 
(PUF)  high-volume air sampler (Tisch 
Environmental, Inc., Village of Cleves, OH, 
USA), which simultaneously collects total 
suspended particles and airborne pollutant 
vapors, meeting the specifications of U.S. EPA 
method TO-13 (U.S. EPA 1999). We took 
samples for 24 hr at a flow rate of approxi-
mately 0.2 m3/min on quartz microfiber fil-
ters (QFFs; 10.16 cm diameter, grade QM-A; 
Whatman, Maidstone, UK) for trapping par-
ticulate matter and PUF cartridges (63 mm 
diameter, 76 mm long; Tisch) for gas-phase 
pollutants. Before the sampling step, we con-
ditioned the QFFs at 400°C for at least 6 hr, 
and the PUFs using dichloromethane (DCM) 
Soxhlet extraction for 24 hr and then dried 
them in a vacuum desiccator. After the con-
ditioning step, we individually wrapped the 
QFFs and PUFs in aluminum foil, protected 
them in a sealable plastic bag, and kept them 
at –18°C before and after the sampling, until 
analysis. We analyzed the samples within 
2 weeks of collection.
We conducted the sampling campaign 
over 1 year between June 2008 and June 
2009. During this period, we took a total of 
153 samples of matched air and particulate 
matter in three weekly samples over approxi-
mately 4 months in each location (52 samples 
at site 1, 48 samples at site 2, and 53 samples 
at site3). We collected samples during two 
phases in each location, including 2 months 
during a high-temperature period and 
2 months during a low-temperature period, 
to determine whether temperature may influ-
ence PAH values in the atmosphere.
Chemical standards and reagents. We 
measured 18 target PAHs and used five deuter-
ated PAHs as internal standards. Standards for 
Nap, acenaphthylene (AcPy), acenaphthene 
(AcP), fluorene (Flu), phenanthrene (PA), 
anthracene (Ant), FluT, pyrene (Pyr), BaA, 
Chr, BbF, benzo[k]fluoranthene (BkF), BaP, 
and DahA were supplied by Sigma-Aldrich (St. 
Louis, MO, USA). Standards for BjF, benzo[e]
pyrene (BeP), Ind, benzo[g,h,i]perylene 
(BghiP), and the deuterated PAHs (d8-Nap, 
d10-AcP, d10-PA, d12-Chr, and d12-perylene) 
were supplied by Supelco (Bellefonte, PA, 
USA). Dimethylformamide (DMF) was pro-
vided by Merck (Darmstadt, Germany). The 
purity of all standards was > 96%.
DCM with purity > 99.9% (SDS, Peypin, 
France) was used to extract the analytes and 
prepare the standard dilutions. Helium and 
nitrogen gas (99.999% purity) were used for 
the chromatographic analysis and extractions, 
respectively (Carburos Metálicos, Barcelona, 
Spain), and Hyflo Super Cel diatomaceous 
earth (Sigma-Aldrich) was used to fill the 
QFF extraction cells of the pressurized liquid 
extraction (PLE) equipment. Diatomaceous 
earth was conditioned at 400°C for 6 hr and 
then kept in a desiccator.
Sample extraction. We extracted PAHs by 
PLE using Accelerate Solvent Extraction ASE 
200 equipment (DIONEX, Sunnyvale, CA, 
USA) and DCM as solvent. For the pressurized 
solvent extraction of the PUFs, we cut them 
in two pieces using acetone-rinsed scissors and 
then placed them in 33-mL extraction cells. 
Extraction of the PUFs consisted of one cycle 
that began with a preheating step of 5 min and 
a static time of 5 min with a temperature of 
100°C and a pressure of 1,500 psi. Flush vol-
ume was 50%, and purge time was 120 sec. 
We cut the QFFs into small pieces, mixed them 
with diatomaceous earth, and placed them in an 
11-mL cell. Extraction of QFFs was performed 
in two cycles under the same conditions as the 
PUF extraction. The PLE extraction conditions 
Figure 1. Map of the Tarragona region showing the 
location of the main city (Tarragona), the North and 
South Industrial Complexes, and the three sam-
pling points: site 1 (Perafort-Puigdelfí) near the 
North Industrial Complex and site 2 (Tarragona-
Bonavista) and site 3 (Vila-seca) near the South 
Industrial Complex.
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of PUFs and QFFs were optimized in a previ-
ous study (Ras et al. 2009a).
We placed the extract from PLE in a 
100-mL round-bottom flask and added 
400 μL DMF to prevent the evaporation of 
the most volatile PAHs (Lintelmann et al. 
2005). We reduced the extract to the DMF 
volume (400 μL) on a rotary evaporator 
and then transferred it to a 1-mL volumet-
ric flask by adding DCM. We then added 
20 μL of 50 mg/L deuterated PAH solution 
(to obtain an internal standard concentration 
of 1 mg/L), and the volumetric flask was filled 
to the mark with DCM. Recoveries of the 
extraction were > 90% for all target PAHs [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0902855)].
Gas chromatography–mass spectrometry 
analysis. We analyzed extracts in a 6890N 
gas chromatograph coupled with a 5973 inert 
mass spectrometer (Agilent Technologies, Palo 
Alto, CA, USA), using a capillary column 
Zebron ZB-5 (5% phenyl, 95%   dimethyl 
polysiloxane, 30 m × 0.25 mm i.d. × 0.25 μm; 
Phenomenex, Le Pecq Cedex, France). The 
gas chromatography–mass spectrometry 
(GC-MS) analysis was performed by injecting 
1 μL extract at 270°C, in splitless mode, at a 
helium constant flow of 1 mL/min. The oven 
temperature program started at 100°C, held 
for 4 min, was raised to 290°C at a rate of 
6°C/min, and held there for 10 min.
The GC-MS interface was set at 280°C. 
The mass spectrometer acquired data in scan 
mode with an m/z interval from 35 to 280, 
operating at electron impact energy of 70 eV. 
Qualitative identification of target PAHs was 
based on the match of the retention times 
and the ion ratios of the target quantifier and 
qualifier ions. We quantified the isomers BjF 
and BbF together because they coelute and 
exhibit similar mass spectra.
We used the internal standard calibration 
method for GC-MS quantification. The stan-
dards, diluted in DCM, ranged between 0.01 
and 50 mg/L with an internal standard con-
stant concentration of 1 mg/L. We prepared all 
the standards on the day of use and kept them 
refrigerated. For an average air preconcentra-
tion of 300 m3, limits of detection (LODs) 
ranged from 0.002 ng/m3 to 0.033 ng/m3, 
and limits of quantification (LOQs) from 
0.033 ng/m3 to 0.167 ng/m3. Repeatability 
and reproducibility were below the 10% rela-
tive standard deviation (RSD) (n = 5) for all 
target compounds. For further information 
about the validation parameters of the ana-
lytical method, see Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901233).
Quality assurance. Because of the ubiqui-
tous presence of PAHs in the atmosphere, pre-
cautions to avoid sample contamination were 
taken throughout the entire process. In addi-
tion to the precautions mentioned previously, 
we followed U.S. EPA method TO-13 (U.S. 
EPA 1999) guidelines. Furthermore, com-
ponents of the extraction cells and collecting 
vials were ultrasound-cleaned with isopro-
panol followed by DCM and dried inside 
a fume cupboard. All glassware, including 
GC syringes, was rinsed three times with iso-
propanol and three times with DCM before 
use. Field blanks, process blanks, and solvent 
blanks were also performed according to sec-
tion 14 of method TO-13. Taking these pre-
cautions into account, no blank showed any 
detectable signals for the target PAHs.
Toxic equivalency factors: BaP equiva-
lency. For risk assessment calculations, we 
ranked the 18 target PAHs according to 
their cancer potency relative to BaP. Most of 
the TEFs used in this study were proposed 
by Larsen and Larsen (1998) based on cur-
rent knowledge of PAH carcinogen effects. 
However, for volatile PAHs such as Nap, 
AcPy, and AcP, we applied TEFs proposed by 
Nisbet and Lagoy (1992).
We calculated BaP equivalents (BaP-eq) 
by multiplying each individual PAH con-
centration with its corresponding TEF and 
determined the concentration of total PAH 
expressed as BaP-eq. Following U.S. EPA 
criteria (U.S. EPA 2000) for risk assessment 
calculations, we substituted half the LOD for 
measured values < LODs and half the LOQ 
value for measured values < LOQs.
Lifetime lung cancer risk of PAHs in the 
atmosphere defined by the WHO unit risk. 
The estimated lifetime lung cancer risk from 
PAHs in the atmosphere based on the WHO 
unit risk (UR) (WHO 2000) is 8.7 cases per 
100,000 people with chronic inhalational 
exposure to 1 ng/m3 BaP (UR = 8.7 × 10–5) 
over a lifetime of 70 years.
The risk of developing lung cancer can 
thus be calculated as
Lifetime lung cancer risk =  
  BaP-eq (ng/m3) × UR.  [1]
We estimated the corresponding annual 
number of lung cancer cases in the popu-
lation around the chemical site that could 
be attributed to PAH as follows: population 
exposed (number of inhabitants) × lifetime 
lung cancer risk ÷ 70 (years of exposure). 
We defined the exposed population for this 
study (170,263 inhabitants) based on the 
proximity to the industrial complexes and the 
prevailing winds.
Results and Discussion
PAH gas and particle phase values. PAHs in 
air can be present either in the gas phase or in 
the particulate phase. The phase distribution 
of the PAHs depends on the vapor pressure 
of the compound, the atmospheric tempera-
ture, the PAH concentration, the affinity of 
the PAH for the atmospheric suspended par-
ticles (determined by the partitioning coeffi-
cients Koc), and the nature and concentrations 
of the particles (ATSDR 1995; Baek et al. 
1991). Table 1 summarizes the PAH con-
centrations we determined. In general, PA 
showed the highest average concentration in 
the gas phase. Nap, Flu, FluT, and Pyr also 
were common gas-phase PAHs, whereas BaA, 
BjF, BkF, and Chr formed most of the par-
ticle phase. Temperature appeared to have a 
considerable influence on PAH concentrations 
because the highest levels of PAHs occurred 
in winter, with Nap, AcPy, AcP, Flu, PA, 
Ant, FluT, BaA, and Chr increasing at lower 
temperatures. Furthermore, in samples col-
lected during the low-temperature periods, 
the heaviest PAHs (BbF, BjF, BkF, BeP, BaP, 
Ind, DahA, BghiP) were present mainly in 
the particulate phase, whereas a more equi-
table distribution of these compounds in 
both phases was observed in samples collected 
during the high-temperature periods. As an 
example, Supplemental Material, Tables 2 and 
3 (doi:10.1289/ehp.0902855), presents the 
daily PAH concentrations obtained in site 1 
over high- and low-temperature periods. For 
instance, in samples collected at site 1 during 
the winter, BaP concentrations in gas-phase 
samples ranged from values under the LOD 
(ND) of each sample to 0.37 ng/m3 and in 
particle-phase samples ranged from 0.14 to 
1.53 ng/m3, whereas in summer concentra-
tions ranged from ND and 1.11 ng/m3 in the 
gas phase and from ND and 1.36 ng/m3 in 
the particle phase. One possible explanation 
is that when the temperature is high, some 
particle-bound PAHs may evaporate and be 
trapped in the PUFs during sampling (U.S. 
EPA 1999).
Although low temperatures facilitate the 
condensation of volatile and semivolatile 
PAHs onto preexisting particles, we found 
that PAH concentrations in the gas phase 
increased more than those in the particle 
phase when temperatures decreased (Table 1). 
This trend has also been reported in previ-
ous studies (Cincinelli et al. 2007; Ravindra 
et al. 2006). One possible explanation may 
be that photochemical reactions with OH 
(hydroxyl) and NO3 (nitrate) radicals increase 
with higher temperatures. However, other 
factors, such as routine plant maintenance 
and seasonal holidays, may also influence sea-
sonal variation in PAH distributions.
In general, the highest total PAH val-
ues were associated with the gas phase in 
both sampling periods, especially in winter 
(Table 1). This trend has been detected in 
previous studies (Ravindra et al. 2006). These 
concentrations in the gas phase may be even 
higher because the trapping efficiency of PUFs 
for the two- to three-ring PAHs is about 35% 
(U.S. EPA 1999).Risk assessment of PAHs near industrial sites
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European legislation only regulates some 
heavy PAHs (BaA, Chr, BbF, BjF, BkF, BaP, 
BeP, DahA) in the particulate phase (European 
Economic Community 2005). Based on results 
we obtained in this study, the current legisla-
tion appears to underestimate the main contri-
bution of PAHs to the atmosphere.
Spatial distribution of PAHs. The volatile 
PAHs (Nap, AcPy, AcP, Flu, PA, Ant) were 
most abundant at all three sampling sites, 
especially in the gas phase, and they made a 
large contribution to the total PAH values 
(between 49% and 84% of the gas phase and 
between 11% and 36% of the particle phase; 
Table 1). Site 1 presented the highest average 
concentrations of PAHs in the particle phase, 
with an average total PAH concentration of 
5.61 ng/m3 in summer and 7.00 ng/m3 in 
winter. Of particular interest are the high 
concentrations of some of the heavy PAHs 
in the gas phase, such as the maximum con-
centrations of DahA or BghiP (5.34 ng/m3 
and 2.19 ng/m3, respectively). Because site 
1 is a rural area, the PAH values primarily 
may reflect activities in the North Industrial 
Complex, particularly refining, which can 
be an important source of particulate phase 
bounded PAHs.
Site 3 presented the highest average 
concentrations for the gas phase, with aver-
age total PAH values of 17.8 ng/m3 in the 
high-temperature season and 67.2 ng/m3 in 
the low-temperature season, whereas site 2 
presented the lowest average values in both 
phases (Table 1). These sites are suburban 
areas near the South Industrial Complex and 
roads with moderate traffic intensity. The 
high maximal PAH values found in the gas 
phase in site 3 could be reflect both traffic 
intensity and industrial activities in the South 
Industrial Complex.
The average total PAH levels of the indus-
trial sites of this study were comparable with 
those measured in industrial sites and in sub-
urban areas in Europe (Cincinelli et al. 2007; 
Ravindra et al. 2006), much higher than those 
previously reported for some urban areas (Ras 
et al. 2009b), and very much higher than 
those reported in high mountain regions of 
Europe (Fernández et al. 2002). The PAH 
levels of the sampling sites therefore seem to 
be related to the activities of the petrochemi-
cal industry in the vicinity.
BaP-eq values of particle- and gas-phase 
PAHs. Table 2 shows the average BaP-eq val-
ues in the gas phase and in the particle phase, 
for the 18 target PAHs and the total PAHs, 
Table 1. Minimum, maximal, and average PAH concentrations (ng/m3) found in the three locations over the two seasonal sampling periods.
Site 1 Site 2 Site 3
Summer Winter Summer Winter–spring Spring Autumn
Min Max Avg Min Max Avg Min Max Avg Min Max Avg Min Max Avg Min Max Avg
Gas phase
Nap ND 3.53 1.37 0.24 20.4 3.92 ND 0.86 0.36 0.48 1.68 0.92 0.24 0.68 0.37 0.53 13.4 2.97
AcPy ND 2.21 0.51 0.31 11.6 3.18 ND 0.60 0.23 0.33 1.29 0.74 ND 0.41 0.28 0.14 15.5 2.89
AcP ND 1.88 0.33 0.15 5.77 1.26 ND 0.47 0.22 0.38 0.93 0.63 0.16 0.98 0.43 0.25 8.26 2.31
Flu 0.39 1.62 0.69 0.42 14.4 5.52 ND 0.84 0.41 0.70 2.10 1.42 0.53 2.66 1.35 0.24 33.0 6.95
PA 0.80 2.46 1.43 1.26 91.1 28.2 0.54 2.23 1.13 1.69 8.57 4.15 1.29 25.3 12.1 0.31 197 35.2
Ant ND 1.58 0.64 0.19 9.00 2.66 ND 2.27 0.35 0.29 0.70 0.46 0.11 1.07 0.46 ND 17.1 2.43
FluT 0.29 0.94 0.56 0.32 20.4 6.01 0.43 1.18 0.64 0.40 1.74 0.82 0.38 4.39 2.03 0.24 43.3 5.84
Pyr ND 0.83 0.38 0.24 24.1 6.31 ND 0.21 0.05 0.38 1.13 0.76 ND 2.17 0.65 0.23 32.9 4.93
BaA ND 1.11 0.30 ND 1.38 0.58 ND 0.35 0.08 ND 0.46 0.20 ND 0.30 0.27 ND 6.37 0.77
Chr ND 1.26 0.25 0.07 7.43 1.30 ND 0.20 0.02 ND 0.43 0.23 ND 0.45 0.35 ND 2.94 0.46
BbF ND 1.56 0.35 ND 0.13 ND ND 0.78 0.09 ND ND ND ND ND ND ND 9.29 0.63
BjF/BkF ND 1.79 0.78 ND 0.66 0.14 ND 0.95 0.64 ND ND ND ND 0.04 0.04 ND 1.11 0.21
BeP ND 0.17 0.01 ND 0.36 0.04 ND 0.33 0.15 ND ND ND ND 0.13 0.09 ND 2.11 0.27
BaP ND 1.11 0.29 ND 0.37 0.03 ND 0.35 0.17 ND ND ND ND ND ND ND 3.06 0.26
Ind ND 1.15 0.32 ND 0.59 0.09 ND 0.45 0.25 ND ND ND ND 0.44 0.32 ND 2.78 0.33
DahA ND 5.34 0.50 ND 0.89 0.17 ND 0.77 0.51 ND 0.57 0.02 ND 0.71 0.60 ND 3.82 0.46
BghiP ND 2.19 0.29 ND 0.74 0.09 ND 0.35 0.23 ND ND ND ND 0.51 0.32 ND 3.00 0.32
Total PAH 2.13 28.5 8.99 3.60 167 59.5 2.72 8.48 5.52 5.26 18.2 10.4 4.63 34.6 17.8 2.14 361 67.2
Particle phase
Nap ND 3.28 0.24 ND 0.11 0.04 ND 0.72 0.16 ND 0.72 0.21 ND 0.28 0.07 ND 0.33 0.14
AcPy ND 2.52 0.10 ND 0.10 0.01 ND 0.54 0.12 ND 0.24 0.04 ND ND ND ND 0.12 ND
AcP ND 1.53 0.11 ND 0.17 0.04 ND 0.59 0.16 ND 0.31 0.14 ND 0.43 0.09 ND 0.42 0.05
Flu ND 0.95 0.08 ND 0.31 0.08 ND 0.40 0.08 ND 0.36 0.05 ND ND ND ND 0.13 0.01
PA ND 1.11 0.26 ND 1.37 0.37 ND 0.32 0.15 ND 0.15 0.01 ND 0.68 0.04 ND 0.17 0.06
Ant ND 1.45 0.26 ND 0.44 0.20 ND 0.36 0.12 ND 0.31 0.20 ND 0.27 0.04 ND 0.14 0.01
FluT ND 0.88 0.17 ND 2.28 0.51 ND 0.50 0.31 ND 0.28 0.12 ND 0.41 0.07 ND 0.37 0.11
Pyr ND 3.44 0.38 0.32 1.57 0.63 ND 0.17 0.05 ND 0.39 0.26 ND 0.21 0.05 ND 0.34 0.15
BaA ND 2.67 0.37 0.12 3.44 0.99 ND 0.32 0.11 0.20 0.59 0.34 ND 0.30 0.19 ND 1.05 0.17
Chr ND 3.44 0.39 0.11 1.88 0.75 ND 0.17 0.04 0.27 0.49 0.38 ND 0.45 0.09 ND 1.25 0.17
BbF ND 2.67 0.44 ND 0.07 ND ND 0.37 0.11 ND ND ND ND 0.04 ND ND 0.13 0.01
BjF/BkF ND 2.39 1.05 ND 1.93 1.03 ND 1.57 0.75 ND 0.20 0.04 ND ND ND ND 1.63 0.27
BeP ND 0.12 0.06 0.14 0.38 0.23 ND 0.50 0.25 ND ND ND ND 0.17 0.03 ND 0.17 0.06
BaP ND 1.36 0.39 0.14 1.53 0.84 ND 0.45 0.24 ND 0.46 0.02 ND ND ND ND 0.46 0.09
Ind ND 2.25 0.48 ND 0.96 0.60 ND 0.76 0.35 ND 0.45 0.10 ND ND ND ND 0.19 0.02
DahA ND 1.86 0.42 ND 0.87 0.26 ND 0.82 0.54 ND ND ND ND ND ND ND ND ND
BghiP ND 1.53 0.47 ND 1.20 0.65 ND 0.55 0.29 ND 0.37 0.10 ND ND ND ND 0.28 0.07
Total PAH 0.61 33.3 5.61 1.08 14.4 7.00 0.46 7.71 3.82 1.16 3.72 2.01 ND 1.65 0.67 ND 5.94 1.39
Sampling period 02/06/08–30/07/08 01/12/08–04/02/09 04/08/08–25/09/08 11/02/09–08/04/09 20/04/09–17/06/09 29/09/08–26/11/08
No. samples 26 26 22 26 26 27
Average temperature 23.2 ± 2.5 9.0 ± 2.5 25.0 ± 2.7 12.0 ± 1.5 20.5 ± 2.8 15.5 ± 4.3
Percent PAHs Air/PM 62.0/38.0 89.5/10.5 59.1/40.9 83.8/16.2 96.4/3.6 98.0/2.0
Abbreviations: Avg, average; Max, maximum; Min, minimum; ND, not detected (values under the limit of detection); PM, particulate matter.Ramírez et al.
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by site and sampling period, and the TEFs 
applied for the 18 PAHs. We also indicate the 
individual PAH compounds that we quanti-
fied in < 15% of the samples.
The contribution of the gas phase to the 
total BaP-eq values in this study was substan-
tial, with values ranging between 34% and 
86%. This high contribution was due to the 
presence of some heavy PAHs in the gas phase 
with high TEFs, and the high concentrations 
of the most volatile PAHs in the gas phase.
It is worth noting that BaP-eq values for 
the particle phase were higher than those for 
the gas phase in winter in site 1 but compa-
rable between the particle and gas phases in 
summer at this site, and comparable between 
the two phases during both seasons at site 2 
(Table 2). For site 3, the major contribu-
tion to total BaP-eq came from the gas phase 
because of the low concentrations of heavy 
PAHs, such as BaP and DahA, in particle-
phase samples from this site. Site 1 showed 
the highest total BaP-eq for the combined gas 
and particle phases in summer (2.073 ng/m3) 
and in winter (1.992 ng/m3).
Lifetime lung cancer risk of 18 PAHs in 
the atmosphere. Figure 2A shows the average 
lifetime lung cancer risk estimated for each 
PAH, by sampling site and sampling period. 
Site 1 showed the highest estimated risk with 
values of 1.8 × 10–4 (1.8 additional cases 
per 10,000 people exposed) for the summer 
period and 1.7 × 10–4 for the winter period. 
In the 2008 sampling periods, site 2 and site 
3 had estimated lifetime lung cancer risks of 
1.5 × 10–4 and 1.4 × 10–4, corresponding to 
a summer and autumn season, respectively, 
that are consistent with estimates for site 1. 
However, in the 2009 sampling periods the 
estimated risks for site 2 and site 3 were 2.2 × 
10–5 (winter–spring) and 2.9 × 10–5 (spring), 
respectively, which were much lower than 
those estimated for 2008. These differences 
could reflect external factors, such as the inter-
national economic crisis that affected many 
industries located at the chemical site and 
probably caused reductions in production or 
shutdowns of some chemical plants (AEQT 
2009), thus changing emissions.
Concerning the individual toxicity of the 
target PAHs, the compounds that contrib-
uted most to the total estimated risk were 
BaP (19–45%), DahA (24–67%), and FluT 
(2–32%; combined contribution, between 
81% and 92%). The contribution of FluT 
that we found mainly in the gas phase and 
that had high values in site 1 in winter and 
Table 2. Average BaP-eq (ng/m3) for gas and particle phases in the three sampling sites, during two seasonal sampling periods.
Site 1 (gas/particle phase) Site 2 (gas/particle phase) Site 3 (gas/particle phase)
PAH TEFa Summer Winter Summer Winter–spring Spring Autumn
Nap 0.001 1.4 × 10–3 / 2.5 × 10–4b 4.2 × 10–3 / 5.0 × 10–5 3.7 × 10–4 / 1.6 × 10–4 9.2 × 10–4 / 2.1 × 10–4 3.7 × 10–4 / 7.0 × 10–5 3.0 × 10–3 / 1.3 × 10–4
AcPy 0.001 5.2 × 10–4 / 1.9 × 10–4b 3.4 × 10–3 / 3.0 × 10–5 2.3 × 10–4 / 1.3 × 10–4 7.4 × 10–4 / 5.0 × 10–5 1.2 × 10–4 / 2.0 × 10–5b 3.0 × 10–3 / 2.5 × 10–5b
AcP 0.001 3.1 × 10–4 / 1.2 × 10–4b 1.3 × 10–3 / 4.0 × 10–5 2.1 × 10–4 / 1.7 × 10–4 6.3 × 10–4 / 1.5 × 10–4 4.2 × 10–4 / 1.0 × 10–4 2.2 × 10–3 / 5.0 × 10–5
Flu 0.0005 3.5 × 10–4 / 5.0 × 10–5 3.0 × 10–3 / 3.5 × 10–5 2.1 × 10–4 / 4.5 × 10–5 7.1 × 10–4 / 3.0 × 10–5 6.8 × 10–4 / 8.0 × 10–6b 3.6 × 10–3 / 2.5 × 10–5b
PA 0.0005 7.1 × 10–4 / 1.3 × 10–4 1.5 × 10–2 / 1.9 × 10–4 5.7 × 10–4 / 7.5 × 10–5 2.1 × 10–3 / 2.0 × 10–5 6.2 × 10–3 / 3.0 × 10–5b 1.9 × 10–2 / 3.5 × 10–5
Ant 0.0005 3.4 × 10–4 / 1.4 × 10–4 1.4 × 10–3 / 9.5 × 10–5 1.8 × 10–4 / 6.5 × 10–5 2.3 × 10–4 / 1.0 × 10–4 2.3 × 10–4 / 3.0 × 10–5 1.3 × 10–3 / 2.5 × 10–5b
FluT 0.05 2.8 × 10–2 / 8.0 × 10–3 0.32 / 2.5 × 10–2 3.2 × 10–2 / 1.5 × 10–2 4.1 × 10–2 / 6.0 × 10–3 0.11 / 3.5 × 10–3 0.31 / 5.5 × 10–3
Pyr 0.001 3.8 × 10–4 / 3.8 × 10–4 6.8 × 10–3 / 6.2 × 10–4 5.0 × 10–5 / 5.0 × 10–5 7.6 × 10–4 / 2.0 × 10–4 6.4 × 10–4 / 6.0 × 10–5 5.3 × 10–3 / 1.5 × 10–4
BaA 0.005 1.5 × 10–3 / 1.9 × 10–3 3.1 × 10–3 / 4.6 × 10–3 4.0 × 10–4 / 5.5 × 10–4 1.0 × 10–3 / 1.7 × 10–3 2.7 × 10–4 / 1.0 × 10–4 4.3 × 10–3 / 8.5 × 10–4
Chr 0.03 7.5 × 10–3 / 1.2 × 10–2 4.2 × 10–2 / 2.3 × 10–2 6.0 × 10–4 / 1.2 × 10–3 6.9 × 10–3 / 1.1 × 10–2 2.1 × 10–3 / 3.0 × 10–3 1.5 × 10–2 / 5.4 × 10–3
BbF 0.1 3.5 × 10–2 / 4.6 × 10–2 2.0 × 10–3b / 2.0 × 10–3 9.0 × 10–3 / 1.2 × 10–2 1.0 × 10–3b / 1.0 × 10–3b 1.0 × 10–3b / 1.0 × 10–3b 7.1 × 10–2 / 2.0 × 10–3
BjF/BkF 0.05 3.9 × 10–2 / 4.9 × 10–2 7.5 × 10–3 / 5.2 × 10–2 3.2 × 10–2 / 3.7 × 10–2 5.0 × 10–5b / 2.0 × 10–3 1.5 × 10–4b / 1.5 × 10–4b 1.1 × 10–2 / 1.5 × 10–2
BeP 0.002 2.0 × 10–5 / 1.8 × 10–4b 8.0 × 10–5b / 4.8 × 10–4 3.6 × 10–4 / 5.8 × 10–4 2.0 × 10–6b / 2.0 × 10–5b 1.8 × 10–5b / 6.6 × 10–5 5.8 × 10–4 / 1.4 × 10–4
BaP 1 0.30 / 0.40 5.0 × 10–2 / 0.85 0.15 / 0.21 2.0 × 10–2b / 6.0 × 10–2b 2.7 × 10–2b / 3.8 × 10–3b 0.28 / 0.14
Ind 0.1 3.2 × 10–2 / 4.7 × 10–3 1.0 × 10–2 / 6.1 × 10–2 2.5 × 10–2 / 3.5 × 10–2 2.0 × 10–3b / 1.3 × 10–2 6.4 × 10–3 / 1.6 × 10–3b 3.9 × 10–2 / 8.0 × 10–3
DahA 1.1 0.56 / 0.48 0.21 / 0.27 0.56 / 0.59 4.4 × 10–2b / 4.4 × 10–2b 0.12 / 1.8 × 10–2b 0.58 / 4.4 × 10–2b
BghiP 0.02 6.0 × 10–3 / 9.4 × 10–3 2.0 × 10–3 / 1.3 × 10–2 4.6 × 10–3 / 6.0 × 10–3 4.0 × 10–4b / 2.6 × 10–3 1.3 × 10–3 / 3.2 × 10–4b 7.6 × 10–3 / 2.4 × 10–3
Total PAHs 
(gas/PM)
1.014 / 1.059 0.685 / 1.307 0.817 / 0. 913 0.122 / 0.143 0.272 / 0.067 1.363 / 0.223
Total PAHs 
(gas + PM)
2.073 1.992 1.730 0.265 0.339 1.586
PM, particulate matter. 
aTEFs for Nap, AcPy, and AcP are from Nisbet and Lagoy (1992); all others are from Larsen and Larsen (1998). bLess than 15% of the samples quantified.
Figure 2. (A) Average estimated lifetime lung cancer risk expressed as excess cancer risk per person exposed, by sampling location, by period and PAH. 
(B) Minimum, maximum, and average estimated excess lifetime lung cancer risk per person exposed, in the three sampling sites by period. The vertical lines indi-
cate the ranges of risk obtained with the daily concentrations, and the points mark the average risks.
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in site 3 in autumn was also noteworthy. 
Although FluT is classified as a weak carcino-
gen, it is mutagenic and therefore has a high 
TEF (0.05). BbF, BjF, BkF, Chr, and Ind 
also contributed to the overall risk with maxi-
mum individual contributions between 4% 
and 7%. Although PA had the highest average 
concentration of the individual PAHs at the 
three sampling sites, it made a small contribu-
tion to the overall risk because of its low TEF.
Figure 2B shows the average, maximum, 
and minimum excess lifetime lung cancer 
risks per person exposed by period and sam-
pling site. We estimated an average lifetime 
lung cancer risk of 1.2 × 10–4 (1.2 additional 
cases per 10,000 people exposed) for the study 
area as a whole. This represents the estimated 
risk above the baseline lifetime lung can-
cer risk in the absence of atmospheric PAH 
exposure. Taking into account the calculated 
average lifetime risk and assuming a homoge-
neous exposure of the inhabitants (170,263) 
around the chemical site, 0.3 annual cases of 
lung cancer can be attributed to this PAH 
exposure. Furthermore, in the absence of 
major indoor PAH sources, such as tobacco 
smoking, cooking fumes, and residential 
heating, outdoor PAHs can also substantially 
contribute to indoor PAH levels (Spengler 
et al. 2001).
According to the WHO “Air Quality 
Guidelines for Europe” (WHO 2000), each 
country has to determine its own acceptable 
risk levels. However, the risk estimate for the 
study area was higher than 10–5, the upper-
bound excess lifetime cancer risk recom-
mended by the WHO for carcinogens in 
drinking water (WHO 1993), and higher 
than the 10–6 risk that is the U.S. EPA guide-
line (Robson and Toscano 2007). We there-
fore conclude that the lung cancer risk due 
to these PAH exposures is not negligible and 
should be taken into account for health pro-
tection in the future.
Moreover, as shown in Figure 2B, the 
maximum risk we found was 1 × 10–3 in site 1. 
Even though this risk corresponds to one 
episode, this result is higher than the recom-
mended values and would correspond to a defi-
nite risk according to criteria used in similar 
risk assessment studies (Sexton et al. 2007).
QRA is a powerful tool to derive a quan-
titative estimate of risk that can be used to 
inform environmental legislation. However, 
QRA has also areas of uncertainty that should 
be taken into account. There are two main 
uncertainties in the case of PAHs: the TEF 
values, which were established from toxicologi-
cal animal studies, and the value of BaP UR, 
which was extrapolated from the results of 
epidemiological studies with exposure to high 
concentrations and can be biased in some 
cases, according to recent studies (Armstrong 
et al. 2004).
Finally, although the U.S. EPA has 
demon  strated that the reestimation of risk 
substituting the nondetected values with half 
the LOD and the nonquantified values with 
half the LOQ did not significantly affect risk 
assessment calculations by itself, the contribu-
tion of the compounds quantified in < 15% 
of the samples can be overestimated. In such 
cases, the use of statistical imputation meth-
odologies for risk estimation has been sug-
gested (U.S. EPA 2000).
Conclusions
In this study, we determined 18 PAHs in 153 
matched samples of atmospheric air and par-
ticulate matter from three sampling locations 
around a chemical site. PAH values were gen-
erally higher in low-temperature periods than 
in high-temperature periods, with higher indi-
vidual PAH concentrations observed in the gas 
phase, especially for the most volatile PAHs.
Risk calculations showed that the contri-
bution of the gas-phase PAHs to the total risk 
should be taken into account, as well as the con-
tribution of volatile PAHs, such as FluT, and of 
the heaviest PAHs, such as BaP or DahA, espe-
cially during high-temperature periods.
The average estimated lifetime lung can-
cer risk for our study area was higher than 
the WHO and the U.S. EPA recommended 
values but lower than the threshold value of 
10–3 considered a definite risk according to 
criteria used in similar risk assessment studies. 
Despite uncertainties associated with the sam-
pling methodology and QRA calculations, 
our findings suggest that it would be prudent 
to take PAH concentrations in both gas and 
particle phases into account in future health-
risk legislation. The real risk values may other-
wise be underestimated.
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